For example, activation of glucagon family receptors (GLP1R, GIPR, GCGR) shows therapeutic efficacy in treating type-2 diabetes and obesity45; however, these receptors are expressed in multiple tissues.46 The contribution of tissue-specific pharmacology to overall therapeutic efficacy and side effect profiles is unclear. Here, GIPR is linked to type 2 diabetes mellitus.